Diabetes roars, partnerships stall—and the street is unconvinced

Sanofi's Q1 FY-2027 result reveals a company in two distinct modes. The diabetes franchise—Lantus, Toujeo, Soliqua—is firing on all cylinders: 17% half-year growth, 70% public sector expansion (CGHS, ESI, Railway, Army, new state accounts), and market share gains in basal insulin (47% value/volume combined). Margins expanded handsomely to 26.3% OPM. But the partnerships with Emcure and Cipla are limping along at 2% growth, dragging overall revenue to just +7.7% YoY. And on the call, when analysts pressed management on whether diabetes can sustain 14% growth, Deepak Arora dodged: "I don't know whether it's 14%, 15%, or 10%." That hedge—and the street's 2.68% fade by day 5—tells you the market isn't buying the upside story yet.

Revenue of ₹437.7 Cr (+7.7% YoY) is respectable but ordinary. Peel away the numbers: domestic revenue was +8%, but export fell -2%. The diabetes core grew 17% in H1; partnership grew 2%. A quarter-over-quarter view is starker—revenue down 7.3%, PAT down 18.6%—though management acknowledged this is partly a tough seasonal comparison (Q1 2025 had safety stock build and sales returns, now lapping unfavorably). The honest core is diabetes is roaring, but the portfolio weight of partnerships (Emcure, Cipla for cardio, CNS, OADs) is dragging overall results. Strip out that drag and the organic growth story is much stronger.

Diabetes trajectory upgraded. Prior guidance spoke to "continued strong growth" in diabetes; H1 delivery of +17% (with 70% public sector growth) exceeds that and validates the strategic focus on Toujeo, Soliqua, and public sector access programs. This is a concrete upgrade to conviction.

Partnership recovery delayed. The prior call (FY-2026 wrap) implied stabilization by year-end 2026. Rachid now says recovery is "maybe 2026, definitely 2027"—a 6-12 month slip. Analysts pressed hard (Rajkumar Vaidyanathan flagged 2% as structural weakness); management acknowledged it's real and deferred to 2027 without giving a firm timeline. This is a downgrade.

Novo Nordisk Awiqli competitive threat newly surfaced. Awiqli (once-weekly long-acting insulin) has launched. Management claims patient profiles differ (once-daily vs once-weekly) and says "too early to comment" on share impact. This is a new risk not previously disclosed, and the deflection suggests real uncertainty.

The stock closed pre-result at ₹3394.3. Post-result: day-1 decline of 1.94% (delivery 54.2%), fading further to -2.68% by day 5. That fade is the market's own verdict—the print didn't hold conviction. At ₹3242.9, the stock is 33.79% below its all-time high and trading below its 20-day (₹3348.78), 50-day (₹3341.5), and 200-day (₹3758.25) moving averages. RSI sits at 36 (neutral-to-weak). Volume is decreasing. The drawdown is material, and the trend is bearish.

Ownership flows tell the same story. FII holdings ticked up 5bp to 5.69%, essentially flat. But DIIs trimmed 1.26 percentage points to 19.87%—a modest but telling pullback. Promoters remain steady at 60.40%, but the domestic money is rotating away. A stock that is both off its highs and losing domestic institutional interest is flagging a conviction problem. The thesis needs to re-anchor.